1. Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients
- Author
-
Chen Chen, Minglei Zhuo, Di Wu, Yujia Chi, Sheng Li, Yuyan Wang, Xue Yang, Jingjing Wang, Zhi Dong, Rong Zhang, Meina Wu, Jia Zhong, Junfeng Li, Xiaoyu Zhai, Qingwei Ma, Hanxiao Chen, Jian Fang, Song Cui, Jie Zhang, Menglei Ma, Yang Wang, Tongtong An, Jianjie Li, Xinghui Zhao, Ziping Wang, Jun Zhao, and Bo Jia
- Subjects
Oncology ,Lung adenocarcinoma ,Cancer Research ,medicine.medical_specialty ,Bevacizumab ,medicine.medical_treatment ,Subgroup analysis ,Pemetrexed ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,First line therapy ,Internal medicine ,Genetics ,medicine ,VeriStrat ,lcsh:QH573-671 ,030304 developmental biology ,0303 health sciences ,Chemotherapy ,Lung ,business.industry ,lcsh:Cytology ,medicine.disease ,Prognosis ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Treatment ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Adenocarcinoma ,Veristrat ,business ,Primary Research ,medicine.drug - Abstract
Background Although advanced non-squamous non-small cell lung cancer (NSCLC) patients have significantly better survival outcomes after pemetrexed based treatment, a subset of patients still show intrinsic resistance and progress rapidly. Therefore we aimed to use a blood-based protein signature (VeriStrat, VS) to analyze whether VS could identify the subset of patients who had poor efficacy on pemetrexed therapy. Methods This study retrospectively analysed 72 advanced lung adenocarcinoma patients who received first-line pemetrexed/platinum or combined with bevacizumab treatment. Results Plasma samples from these patients were analysed using VS and classified into the Good (VS-G) or Poor (VS-P) group. The relationship between efficacy and VS status was further investigated. Of the 72 patients included in this study, 35 (48.6%) were treated with pemetrexed plus platinum and 37 (51.4%) were treated with pemetrexed/platinum combined with bevacizumab. Among all patients, 60 (83.3%) and 12 (16.7%) patients were classified as VS-G and VS-P, respectively. VS-G patients had significantly better median progression-free survival (PFS) (Unreached vs. 4.2 months; P Conclusions Our study indicated that VS might be considered as a novel and valid method to predict the efficacy of pemetrexed-based therapy and identify a subset of advanced lung adenocarcinoma patients who had intrinsic resistance to pemetrexed based regimens. However, larger sample studies are still needed to further confirm this result.
- Published
- 2020